HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cannabis Trade Group Threatens FSA With Legal Action As CBD Novel Food Row Intensifies

Executive Summary

Cannabis trade association CannaPro is threatening legal action against the UK's Food Standards Agency for its response to moves by EU regulators to classify CBD as a novel Food. The FSA's handling of the situation is negatively impacting business, states CannaPro, which has warned the agency it will sue for damages.  

You may also be interested in...



UK CBD Firms Given Deadline For EU Compliance

BREAKING NEWS: UK food regulator, FSA, has given CBD firms until the 31 March 2021 to submit valid novel food applications under new EU rules. FSA says it will not take products off shelves until then, but has also warned some consumers against taking CBD due to "potential adverse health effects."

CBD Industry Group Commits To Compliance With EU Novel Food Law

Seeking to end the current impasse between regulators and the CBD industry, the Centre For Medicinal Cannabis is launching a quality charter for its members to put their products “on the path to regulatory compliance.” 

European CBD Market Snapshot: UK Leads As Retailers Get On Board With FSA Decision Pending

The UK's cannabidiol market, which according to the Cannabis Trades Association is the largest in Europe, awaits clarification on the legal status of CBD-containing food supplements. Meanwhile, major retailers like Walgreen Boots Alliance are stepping into the space with branded products. 

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel